$ONCT
Oncternal Therapeutics Inc

2020 Q1 Form 10-K Financial Statement

#000156459020011213 Filed on March 16, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 2018 Q4
Revenue $578.0K $2.425M $0.00
YoY Change 22.98% -3.81%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.630M $7.290M $2.350M
YoY Change 182.8% -22.36% -5.62%
% of Gross Profit
Research & Development $0.00 $0.00 $3.240M
YoY Change -53.11%
% of Gross Profit
Depreciation & Amortization $20.00K
YoY Change 100.0%
% of Gross Profit
Operating Expenses $5.329M $35.53M $5.590M
YoY Change 88.44% 251.57% -40.53%
Operating Profit -$4.751M -$33.11M
YoY Change 101.48%
Interest Expense $10.00K $190.0K
YoY Change -80.0% 18900.0%
% of Operating Profit
Other Income/Expense, Net $13.00K -$1.080M $170.0K
YoY Change -79.69% -268.75% 41.67%
Pretax Income -$4.740M -$34.19M -$5.420M
YoY Change 106.99% -11.01% -41.59%
Income Tax
% Of Pretax Income
Net Earnings -$4.738M -$34.19M -$5.420M
YoY Change 106.54% 419.65% -41.59%
Net Earnings / Revenue -819.72% -1409.81%
Basic Earnings Per Share
Diluted Earnings Per Share -$308.6K -$3.310M -$32.19K
COMMON SHARES
Basic Shares Outstanding 15.39M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.00M $20.10M $28.50M
YoY Change -24.53% -29.47% -35.08%
Cash & Equivalents $16.02M $20.10M $20.65M
Short-Term Investments $200.0K
Other Short-Term Assets $500.0K $700.0K $2.800M
YoY Change -61.54% -75.0% 27.27%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $16.56M $20.80M $21.21M
YoY Change -26.38% -33.33% -53.99%
LONG-TERM ASSETS
Property, Plant & Equipment $200.0K $200.0K $0.00
YoY Change -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.047M $800.0K $752.0K
YoY Change
Total Long-Term Assets $1.201M $900.0K $752.0K
YoY Change 1101.0% 800.0% 652.0%
TOTAL ASSETS
Total Short-Term Assets $16.56M $20.80M $21.21M
Total Long-Term Assets $1.201M $900.0K $752.0K
Total Assets $17.77M $21.70M $21.96M
YoY Change -21.39% -30.67% -52.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.376M $900.0K $3.440M
YoY Change 129.33% -72.73% 32.31%
Accrued Expenses $2.778M $2.800M $891.0K
YoY Change 131.5% 2700.0% -83.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.317M $7.300M $4.331M
YoY Change 306.5% 40.38% -45.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $100.0K $100.0K
YoY Change
Total Long-Term Liabilities $100.0K $100.0K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $7.317M $7.300M $4.331M
Total Long-Term Liabilities $100.0K $100.0K $0.00
Total Liabilities $7.400M $7.400M $5.200M
YoY Change 311.11% 42.31% -35.0%
SHAREHOLDERS EQUITY
Retained Earnings -$70.31M -$31.38M
YoY Change
Common Stock $15.00K $5.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.40M $14.30M -$29.63M
YoY Change
Total Liabilities & Shareholders Equity $17.77M $21.70M $21.96M
YoY Change -21.39% -30.67% -52.46%

Cashflow Statement

Concept 2020 Q1 2019 2018 Q4
OPERATING ACTIVITIES
Net Income -$4.738M -$34.19M -$5.420M
YoY Change 106.54% 419.65% -41.59%
Depreciation, Depletion And Amortization $20.00K
YoY Change 100.0%
Cash From Operating Activities -$4.036M -$16.75M -$9.620M
YoY Change 11.09% 125.78% -1.13%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $16.14M $14.78M
YoY Change -100.0% -42.11% -153.01%
Cash From Investing Activities $0.00 $16.14M $14.78M
YoY Change -100.0% -42.12% -152.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.000K 15.00K 0.000
YoY Change 100.0% -99.92%
NET CHANGE
Cash From Operating Activities -4.036M -16.75M -9.620M
Cash From Investing Activities 0.000 16.14M 14.78M
Cash From Financing Activities 4.000K 15.00K 0.000
Net Change In Cash -4.032M -594.0K 5.160M
YoY Change 8.68% -105.68% -113.72%
FREE CASH FLOW
Cash From Operating Activities -$4.036M -$16.75M -$9.620M
Capital Expenditures $0.00
Free Cash Flow -$9.620M
YoY Change -1.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2019 dei Local Phone Number
LocalPhoneNumber
434-1113
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20051000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
736000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
565000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
20787000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
190000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
767000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
752000
CY2019Q4 us-gaap Assets
Assets
21744000
CY2018Q4 us-gaap Assets
Assets
21962000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
871000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3440000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2731000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
891000
CY2019Q4 us-gaap Deferred Revenue
DeferredRevenue
3640000
CY2018Q4 onct Preferred Stock Warrant Liability
PreferredStockWarrantLiability
674000
CY2018Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
46588000
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1748000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-31384000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-29631000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21962000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15387000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3762000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15387000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3762000
CY2019 us-gaap Revenues
Revenues
2425000
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 dei Trading Symbol
TradingSymbol
ONCT
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-12-31
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001260990
CY2019 dei Entity Registrant Name
EntityRegistrantName
Oncternal Therapeutics, Inc.
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2019 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20645000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
21210000
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
12230 El Camino Real
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
62-1715807
CY2019 dei Entity File Number
EntityFileNumber
000-50549
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
CY2019 dei City Area Code
CityAreaCode
858
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15387242
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019Q2 dei Entity Public Float
EntityPublicFloat
62400000
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.31
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.83
CY2019 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
10159000
CY2018 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
8287000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1820000
CY2018 us-gaap Operating Expenses
OperatingExpenses
10107000
CY2018 us-gaap Revenues
Revenues
2521000
CY2019 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
18088000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7286000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15000
CY2019 onct Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-92000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17874000
CY2019 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
3640000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-594000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10457000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20645000
CY2019 us-gaap Operating Expenses
OperatingExpenses
35533000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1255000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4000
CY2018 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
216000
CY2018 us-gaap Interest Expense
InterestExpense
1000
CY2018 us-gaap Investment Income Interest
InvestmentIncomeInterest
79000
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10329
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3591
CY2019 us-gaap Profit Loss
ProfitLoss
-34188000
CY2018 us-gaap Profit Loss
ProfitLoss
-6579000
CY2018 us-gaap Other Noncash Income
OtherNoncashIncome
216000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
507000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
180000
CY2018 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1000
CY2018 onct Noncash Compensation Expense
NoncashCompensationExpense
10000
CY2019 onct Noncash Lease Expense
NoncashLeaseExpense
92000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
44000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
436000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4762000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2242000
CY2018 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1902000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16746000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7417000
CY2019 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
18292000
CY2019 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
2155000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
16137000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
14000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000
CY2019 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1000
CY2018 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
17873000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10188000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20051000
CY2019 onct Conversion Of Convertible Preferred Stock To Common Stock
ConversionOfConvertiblePreferredStockToCommonStock
46588000
CY2019 us-gaap Stock Issued1
StockIssued1
29049000
CY2019 onct Reclassification Of Preferred Stock Warrants Liability To Additional Paid In Capital
ReclassificationOfPreferredStockWarrantsLiabilityToAdditionalPaidInCapital
1942000
CY2019 us-gaap Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
5177000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-23278000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2018 onct Adjustments To Additional Paid In Capital Vesting Related To Repurchase Liability Net
AdjustmentsToAdditionalPaidInCapitalVestingRelatedToRepurchaseLiabilityNet
35000
CY2018 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
10000
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
100000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
65000
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
35000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
180000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14000
CY2019 onct Adjustments To Additional Paid In Capital Exercise Of Warrants To Purchase Common Stock For Cash
AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash
1000
CY2019 onct Adjustments To Additional Paid In Capital Vesting Related To Repurchase Liability Net
AdjustmentsToAdditionalPaidInCapitalVestingRelatedToRepurchaseLiabilityNet
30000
CY2019 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
29049000
CY2019 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
46588000
CY2019 onct Adjustments To Additional Paid In Capital Reclassification Of Convertible Preferred Stock Warrant
AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant
1942000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
507000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
504019
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1230000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
52726
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
12000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
166000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
41000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
207000
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
17000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
190000
CY2019 us-gaap General Insurance Expense
GeneralInsuranceExpense
1200000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0
CY2019Q2 onct Common Stock Shares Outstanding Prior To Stock Split
CommonStockSharesOutstandingPriorToStockSplit
3458170
CY2019Q2 us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
29049000
CY2019Q2 us-gaap Noncash Merger Related Costs
NoncashMergerRelatedCosts
2154000
CY2019Q2 onct Asset Acquisition Purchase Price
AssetAcquisitionPurchasePrice
31203000
CY2019Q2 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
18292000
CY2019Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
-5177000
CY2019Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
18088000
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 onct Liability For Unvested Cash Settled Share Based Payment Transactions
LiabilityForUnvestedCashSettledShareBasedPaymentTransactions
24000
CY2018Q4 onct Liability For Unvested Cash Settled Share Based Payment Transactions
LiabilityForUnvestedCashSettledShareBasedPaymentTransactions
54000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2834
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9124
CY2019Q4 onct Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
1206000
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:-0.35pt;"> </font><font style="letter-spacing:0.1pt;">Company&#8217;s</font><font style="letter-spacing:-0.5pt;"> </font><font style="letter-spacing:0.15pt;">consolidated</font><font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.1pt;">financial</font><font style="letter-spacing:-0.25pt;"> </font><font style="letter-spacing:0.1pt;">statements</font><font style="letter-spacing:-0.45pt;"> </font>are<font style="letter-spacing:-0.35pt;"> </font>prepared<font style="letter-spacing:-0.2pt;"> </font>in<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.1pt;">accordance</font><font style="letter-spacing:-0.35pt;"> </font>with<font style="letter-spacing:-0.15pt;"> GAAP.</font><font style="letter-spacing:-0.6pt;"> </font>The<font style="letter-spacing:-0.35pt;"> </font>preparation<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.15pt;">of</font><font style="letter-spacing:-0.65pt;"> </font><font style="letter-spacing:0.15pt;">the</font><font style="letter-spacing:-0.3pt;"> </font><font style="letter-spacing:0.1pt;">Company&#8217;s</font><font style="letter-spacing:-0.45pt;"> </font><font style="letter-spacing:0.15pt;">consolidated</font><font style="letter-spacing:-0.2pt;"> </font><font style="letter-spacing:0.1pt;">financial</font><font style="letter-spacing:-0.2pt;"> </font><font style="letter-spacing:0.1pt;">statements</font><font style="letter-spacing:-0.5pt;"> </font><font style="letter-spacing:0.1pt;">and</font><font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.15pt;">accompanying</font><font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.15pt;">notes</font><font style="letter-spacing:-0.45pt;"> </font>requires<font style="letter-spacing:-0.5pt;"> </font>it<font style="letter-spacing:-0.2pt;"> </font>to<font style="letter-spacing:-0.2pt;"> </font>make<font style="letter-spacing:-0.3pt;"> </font>estimates <font style="letter-spacing:0.1pt;">and assumptions </font><font style="letter-spacing:0.15pt;">that </font><font style="letter-spacing:0.1pt;">impact </font><font style="letter-spacing:0.15pt;">the </font>reported <font style="letter-spacing:0.15pt;">amounts of </font>assets, <font style="letter-spacing:0.15pt;">liabilities, </font><font style="letter-spacing:0.1pt;">revenues and expenses and </font><font style="letter-spacing:0.15pt;">the </font><font style="letter-spacing:0.1pt;">disclosure </font><font style="letter-spacing:0.15pt;">of </font><font style="letter-spacing:0.2pt;">contingent </font>assets <font style="letter-spacing:0.1pt;">and </font><font style="letter-spacing:0.15pt;">liabilities. </font><font style="letter-spacing:0.1pt;">Significant </font>estimates <font style="letter-spacing:0.1pt;">consist </font><font style="letter-spacing:0.15pt;">of those </font>used to determine <font style="letter-spacing:0.15pt;">the </font>fair <font style="letter-spacing:0.15pt;">value of the </font><font style="letter-spacing:0.1pt;">Company&#8217;s </font>preferred <font style="letter-spacing:0.1pt;">stock, </font>preferred <font style="letter-spacing:0.1pt;">stock</font> warrant <font style="letter-spacing:0.15pt;">liability</font> and stock-based awards<font style="letter-spacing:0.15pt;">, </font><font style="letter-spacing:0.1pt;">and </font><font style="letter-spacing:0.15pt;">those </font>used to determine grant <font style="letter-spacing:0.1pt;">revenue and </font>accruals for research <font style="letter-spacing:0.1pt;">and </font><font style="letter-spacing:0.15pt;">development </font>costs. <font style="letter-spacing:0.15pt;">Although </font><font style="letter-spacing:0.1pt;">these </font>estimates are based <font style="letter-spacing:0.15pt;">on the </font><font style="letter-spacing:0.1pt;">Company&#8217;s</font><font style="letter-spacing:-0.45pt;"> </font><font style="letter-spacing:0.15pt;">knowledge</font><font style="letter-spacing:-0.3pt;"> </font><font style="letter-spacing:0.15pt;">of</font><font style="letter-spacing:-0.65pt;"> </font>current<font style="letter-spacing:-0.2pt;"> </font><font style="letter-spacing:0.15pt;">events</font><font style="letter-spacing:-0.45pt;"> </font><font style="letter-spacing:0.1pt;">and</font><font style="letter-spacing:-0.1pt;"> </font><font style="letter-spacing:0.15pt;">actions</font><font style="letter-spacing:-0.45pt;"> </font>it<font style="letter-spacing:-0.2pt;"> </font>may<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.15pt;">undertake</font><font style="letter-spacing:-0.3pt;"> </font>in<font style="letter-spacing:-0.1pt;"> </font><font style="letter-spacing:0.15pt;">the</font><font style="letter-spacing:-0.3pt;"> </font>future,<font style="letter-spacing:-0.6pt;"> </font><font style="letter-spacing:0.1pt;">actual</font><font style="letter-spacing:-0.2pt;"> </font>results<font style="letter-spacing:-0.45pt;"> </font>may<font style="letter-spacing:-0.1pt;"> </font><font style="letter-spacing:0.1pt;">ultimately</font><font style="letter-spacing:-0.15pt;"> </font>materially<font style="letter-spacing:-0.1pt;"> </font>differ<font style="letter-spacing:-0.65pt;"> </font>from<font style="letter-spacing:-0.45pt;"> </font><font style="letter-spacing:0.1pt;">these</font><font style="letter-spacing:-0.3pt;"> </font>estimates <font style="letter-spacing:0.1pt;">and</font><font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:0.1pt;">assumptions.</font></p>
CY2019Q4 onct Preferred Stock Warrant Liability
PreferredStockWarrantLiability
1300000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.29
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.024
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.027
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.753
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.764
CY2018 onct Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term Minimum
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTermMinimum
P3Y8M12D
CY2018 onct Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term Maximum
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTermMaximum
P4Y
CY2018Q4 us-gaap Grants Receivable
GrantsReceivable
100000
CY2019 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
56000
CY2018 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
164000
CY2018Q4 onct Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
720000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
424000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
20000
CY2019Q4 onct Accrued Unvested Share Liability
AccruedUnvestedShareLiability
24000
CY2018Q4 onct Accrued Unvested Share Liability
AccruedUnvestedShareLiability
54000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
825000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
85000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
252000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
12000
CY2019 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
507000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
180000
CY2019Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4200000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y6M
CY2018Q4 onct Redeemable Convertible Preferred Stock Shares Reserved For Future Issuance
RedeemableConvertiblePreferredStockSharesReservedForFutureIssuance
8148000
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
19040
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1662253
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.81
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.47
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.38
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.69
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.17
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.016
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.029
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.776
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.647
CY2018Q4 onct Warrants To Purchase Convertible Preferred Stock Shares Reserved For Future Issuance
WarrantsToPurchaseConvertiblePreferredStockSharesReservedForFutureIssuance
372000
CY2019Q4 onct Common Stock Warrants Reserved For Future Issuance
CommonStockWarrantsReservedForFutureIssuance
841000
CY2019Q4 onct Common Stock Options Issued And Outstanding For Future Issuance
CommonStockOptionsIssuedAndOutstandingForFutureIssuance
1958000
CY2018Q4 onct Common Stock Options Issued And Outstanding For Future Issuance
CommonStockOptionsIssuedAndOutstandingForFutureIssuance
504000
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3294000
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9104000
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-7179000
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1379000
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-968000
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-500000
CY2019 onct Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
873000
CY2018 onct Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
-147000
CY2019 onct Income Tax Reconciliation In Process Research And Development
IncomeTaxReconciliationInProcessResearchAndDevelopment
3354000
CY2019 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
217000
CY2018 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
468000
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
18000
CY2019 onct Valuation Allowance Deferred Tax Asset Change Net Amount
ValuationAllowanceDeferredTaxAssetChangeNetAmount
13100000
CY2019 onct Cumulative Change In Ownership Percentage
CumulativeChangeInOwnershipPercentage
0.50
CY2019 onct Period For Cumulative Change In Ownership
PeriodForCumulativeChangeInOwnership
P3Y
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2019Q1 us-gaap Cumulative Effect On Retained Earnings Tax1
CumulativeEffectOnRetainedEarningsTax1
0
CY2019Q1 onct Adjustment To Deferred Tax Liability
AdjustmentToDeferredTaxLiability
100000
CY2019Q1 onct Adjustment To Deferred Tax Assets
AdjustmentToDeferredTaxAssets
100000
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
51000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
4119000
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2443000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
18108000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
8321000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1446000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1231000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
214000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
24000
CY2019Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
7688000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
143000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
288000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
27599000
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
9864000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
27546000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9864000
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
53000
CY2019Q4 onct Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
53000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
53000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
13100000

Files In Submission

Name View Source Status
0001564590-20-011213-index-headers.html Edgar Link pending
0001564590-20-011213-index.html Edgar Link pending
0001564590-20-011213.txt Edgar Link pending
0001564590-20-011213-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
ggkxr0xdedy4000001.jpg Edgar Link pending
ggkxr0xdedy4000002.jpg Edgar Link pending
ggkxr0xdedy4000003.jpg Edgar Link pending
ggkxr0xdedy4000004.jpg Edgar Link pending
ggkxr0xdedy4000005.jpg Edgar Link pending
ggkxr0xdedy4000006.jpg Edgar Link pending
ggkxr0xdedy4000007.jpg Edgar Link pending
ggkxr0xdedy4000008.jpg Edgar Link pending
ggkxr0xdedy4000009.jpg Edgar Link pending
ggkxr0xdedy4000010.jpg Edgar Link pending
ggkxr0xdedy4000011.jpg Edgar Link pending
ggkxr0xdedy4000012.jpg Edgar Link pending
ggkxr0xdedy4000013.jpg Edgar Link pending
ggkxr0xdedy4000014.jpg Edgar Link pending
ggkxr0xdedy4000015.jpg Edgar Link pending
ggkxr0xdedy4000016.jpg Edgar Link pending
ggkxr0xdedy4000017.jpg Edgar Link pending
ggkxr0xdedy4000018.jpg Edgar Link pending
ggkxr0xdedy4000019.jpg Edgar Link pending
ggkxr0xdedy4000020.jpg Edgar Link pending
ggkxr0xdedy4000021.jpg Edgar Link pending
ggkxr0xdedy4000022.jpg Edgar Link pending
ggkxr0xdedy4000023.jpg Edgar Link pending
ggkxr0xdedy4000024.jpg Edgar Link pending
gu1sdluao0kv000001.jpg Edgar Link pending
gu1sdluao0kv000002.jpg Edgar Link pending
gu1sdluao0kv000003.jpg Edgar Link pending
onct-10k_20191231.htm Edgar Link pending
onct-20191231.xml Edgar Link completed
onct-20191231.xsd Edgar Link pending
onct-20191231_cal.xml Edgar Link unprocessable
onct-20191231_def.xml Edgar Link unprocessable
onct-20191231_lab.xml Edgar Link unprocessable
onct-20191231_pre.xml Edgar Link unprocessable
onct-ex1013_766.htm Edgar Link pending
onct-ex102_765.htm Edgar Link pending
onct-ex1031_767.htm Edgar Link pending
onct-ex1032_768.htm Edgar Link pending
onct-ex211_764.htm Edgar Link pending
onct-ex231_10.htm Edgar Link pending
onct-ex311_694.htm Edgar Link pending
onct-ex312_693.htm Edgar Link pending
onct-ex321_691.htm Edgar Link pending
onct-ex322_692.htm Edgar Link pending
onct-ex45_1133.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending